Company Overview of MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, focuses on discovering and developing antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases. Its advanced clinical product candidate is Margetuximab, a monoclonal antibody that is in Phase III clinical trial, which targets human epidermal growth factor receptor 2-expressing tumors, including certain types of breast and gastroesophageal cancers. The company also develops Enoblituzumab, an antibody that is in Phase 1 clinical trial as monotherapy in multiple dose expansion cohorts; MGD006, a DART molecule that targets CD123 and CD3; ...
9640 Medical Center Drive
Rockville, MD 20850
Founded in 2000
Key Executives for MacroGenics, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $523.0K
Chief Financial Officer, Senior Vice President and Corporate Secretary
Total Annual Compensation: $336.5K
Chief Medical Officer and Senior Vice President of Clinical Development
Total Annual Compensation: $380.8K
Senior Vice President and General Counsel
Total Annual Compensation: $357.7K
Chief Scientific Officer and Senior Vice President of Research
Total Annual Compensation: $353.0K
Compensation as of Fiscal Year 2015.
MacroGenics, Inc. Key Developments
MacroGenics, Inc. Presents at BioNetwork West Partnering Summit 2016, Oct-06-2016 10:50 AM
Oct 3 16
MacroGenics, Inc. Presents at BioNetwork West Partnering Summit 2016, Oct-06-2016 10:50 AM. Venue: The Ritz-Carlton, Laguna Niguel, California, United States. Speakers: Eric Blasius Risser, Chief Business Officer and Senior Vice President of Business Development & Portfolio Management.
MacroGenics, Inc. Announces Executive Promotions
Sep 20 16
MacroGenics, Inc. announced that it has promoted three executives: Ezio Bonvini, M.D., to Senior Vice President, Research and Chief Scientific Officer; Eric Risser to Senior Vice President, Business Development and Portfolio Management and Chief Business Officer; and Thomas Spitznagel, Ph.D., to Senior Vice President, BioPharmaceutical Development and Manufacturing. Dr. Bonvini joined MacroGenics in 2003 and has led the company’s discovery and preclinical activities, which has included the successful advancement of several programs from early discovery to IND submission as well as the development of the Company’s Fc Optimization, DART® and Trident™ antibody-based engineering platforms. Previously, Dr. Bonvini held roles with the Food and Drug Administration in the Center for Biologics Evaluation and Research, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. Mr. Risser joined MacroGenics in 2009 and has played an instrumental leadership role in sourcing, structuring, and negotiating the company’s collaboration partnerships. He is also responsible for MacroGenics’ alliance and program management and new product planning functions. Prior to joining MacroGenics, Mr. Risser held the position of Senior Director, Business Development in the pharmaceutical group at Johnson & Johnson, where he worked from 2003 to 2009. Dr. Spitznagel joined MacroGenics in 2013 and has overall responsibility for biopharmaceutical process development and manufacturing of MacroGenics’ product candidates, including several Fc-optimized monoclonal antibodies and DART molecules, as well as oversight of the facilities and engineering functions. Prior to joining MacroGenics, he was at Human Genome Sciences, most recently serving as Vice President of BioPharmaceutical Development, where he was responsible for oversight of Analytical Development, Formulation and Drug Delivery, Purification Sciences, and Fermentation and Cell Culture Sciences.
MacroGenics, Inc. and Takeda Pharmaceutical Company Limited Announces Conclusion of License Agreement for MGD010
Sep 12 16
MacroGenics, Inc. and Takeda Pharmaceutical Company Limited announced the conclusion of their license and option agreement for MGD010. MacroGenics has regained the worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B. Takeda’s decision comes earlier than the predefined expiration of its option exercise period and follows Takeda’s recently announced therapeutic area re-prioritization. Takeda’s decision was not based on the ongoing Phase 1 study with MGD010. MacroGenics plans to continue to advance the development of this product candidate based on the positive study results reported to date.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|